| 摘要 |
Forms of curcumin and the pharmaceutical compositions thereof. The forms of curcumin disclosed herein are curcumin polymorph Form III, curcumin-2-aminobenzimidazole co-crystal, and curcumin-L-lysine co-crystal. Further, the invention provides methods inhibiting cancer cells and HSV-1 using these curcumin novel solid forms. A co-crystal form of curcumin, the co-crystal form being curcumin-2-aminobenzimidazole. The said co-crystal form, curcumin-2-aminobenzimidazole, exhibits an X-ray powder diffraction pattern having characteristic peaks expressed in degrees 2-theta at about 6.2, about 9.0, about 12.3, about 14.5, about 17.3, about 18.0, about 19.0, about 20.0, about 21.2, about 24.5, about 25.05, and about 27.1. In particular, the co-crystal form, curcumin-2-aminobenzimidazole, exhibits an endothermic transition with an onset of about 118.1 degrees Centigrade as measured by differential scanning calorimetry. |
